Search SIGY
Sigyn Therapeutics, Inc.
OTC · CIK 1642159
Last close0.03
Daily change-0.00 (-5.71%)
10 Years gain-99.94%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SIGY · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
30.5Momentum
n/aAcceleration
n/aConfidence
69.0Annual Revenue5
Quarterly Revenue17
Annual CFO8
Balance SheetMissing
RankingLimited
Score Breakdown
Growth17.3 / 25
Quality11.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 7.662 percentage points.
Key Metrics
Revenue Growth TTM-81.26%OK
Revenue CAGR 3Y69.93%OK
Gross Margin72.55%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 FY Dec 31, 2024 | n/a | $0.00 | -$2.52M | -$872,436.00 | n/a | n/a | n/a | n/a | n/a | 1.33M |
| 2024 FY Dec 31, 2023 | n/a | $0.00 | -$2.46M | -$1.38M | n/a | n/a | n/a | n/a | n/a | 1.1M |
| 2023 FY Dec 31, 2022 | n/a | $0.00 | -$2.15M | -$1.83M | -$1.83M | n/a | n/a | n/a | n/a | 934,915 |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$2.01M | -$1.77M | -$1.80M | n/a | n/a | n/a | n/a | 36.4M |
| 2021 FY Dec 31, 2020 | n/a | $0.00 | -$916,434.00 | -$829,809.00 | n/a | n/a | n/a | n/a | -10,832.39% | 7.35M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $36,690.00 | sum latest 4 fiscal quarters Revenue | OK | 0001753926-20-000359, 0001753926-20-000124 |
| Revenue Growth TTM | -81.26% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001753926-20-000359, 0001753926-20-000124 |
| Revenue CAGR 3Y | 69.93% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001753926-20-000068 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001753926-20-000068 |
| Gross Profit CAGR 3Y | 77.42% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001753926-20-000068 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 72.55% | Gross Profit / Revenue | OK | 0001753926-20-000359, 0001753926-20-000124 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| Current Ratio | 0.17x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001753926-20-000068 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001753926-20-000068 |
| Gross Margin Delta 1Y | -7.66 pp | GrossMargin_current - GrossMargin_prior_year | OK | 0001753926-20-000359, 0001753926-20-000124 |